ALDX - Aldeyra stock jumps 8% on dermatitis drug updates
2023-12-19 11:40:50 ET
More on Aldeyra Therapeutics
- Why I Am Selling Aldeyra Therapeutics: A Sour AbbVie Deal And A Lack Of Transparency
- Aldeyra:Upcoming PDUFA, Strong NDA, Long Pipeline, Decent Cash
- FDA says more data needed to approve Aldeyra dry eye drug (update)
- AbbVie enters option deal for Aldeyra dry eye disease drug
- Seeking Alpha’s Quant Rating on Aldeyra Therapeutics
For further details see:
Aldeyra stock jumps 8% on dermatitis drug updates